china is host to 70 percent of all car cell therapy trials registered in 2017 and the first four months of 2018 (150 out of 214).
.
.: "arise: a phase 3 randomized trial of erenumab for episodic migraine."
.
schneider said that he is "not aware of any relevant risk of the drug" and that his team has "not observed side effects in thousands of treated animals."
.
.
.